CStone Pharmaceuticals (HK:2616) has released an update.
CStone Pharmaceuticals has announced the China NMPA’s approval of their AYVAKIT (avapritinib tablets) manufacturing localization in China, aiming to replace imported products by late 2024 or early 2025. This marks a significant milestone for the company, potentially increasing supply flexibility and market presence in China, while ensuring high-quality, domestically produced drugs for patients. The approval also underscores CStone’s commitment to advanced manufacturing technologies and strict quality management to meet domestic demands.
For further insights into HK:2616 stock, check out TipRanks’ Stock Analysis page.
